Login to Your Account



Pharma: Other News To Note


Thursday, July 18, 2013
• Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said anaprazole sodium, received the approval for clinical studies from the CFDA. Anaprazole sodium is a new generation of proton pump inhibitors (PPIs) for treating ulcers by inhibiting gastric acid secretion and eradicating Helicobacter pylori.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription